Epidemiologic data frompatients with type 2 DM treated with TZDs suggest that these ligands of PPARγ are protective against lung cancer butnot against colon or prostate cancer [50].With the impressive in vitro data and suggestive findings fromepidemiology, oncologists have proposed that PPARγ is an attractive target for cancertreatment. Here, PPARG is linked to prostate cancer.